Randomized Phase II Trial Tests Nivolumab Then Nivolumab-Ipilimumab or Docetaxel
A new randomized Phase II clinical trial, OPTIM, is testing whether escalating immune therapy can improve outcomes for people with ...
A new randomized Phase II clinical trial, OPTIM, is testing whether escalating immune therapy can improve outcomes for people with ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine